WooGene B&G Co., Ltd. announced that it expects to receive KRW 3 billion in funding
January 10, 2020
Share
WooGene B&G Co., Ltd. (KOSDAQ:A018620) announced a private placement of series 4 bearer coupon unguaranteed private convertible bonds for gross proceeds of KRW 3,000,000,000 on January 10, 2020. The bonds will carry an interest of zero per annum and yield to maturity is 2%. The bonds will be issued at its par value. The bonds will mature on January 10, 2024. The bonds are fully convertible into 1,220,504 shares at a conversion price of KRW 2,458 per share. The bonds are convertible from January 15, 2021 to December 15, 2023. The expected date of payment is January 15, 2020. The transaction will include participation from individual investor Jinwoo Hong for KRW 1,060,000,000, Dongjin Heo for KRW 1,040,000,000 and Kyungnam Kim for KRW 900,000,000. The transaction has been approved by board of director of the company.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
